Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has entered a second agreement with Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).

TRB-3 and TRB-4, marking the rapid progression of the Transpire Bio pipeline, are inhaled products being developed for advanced markets. With a focus on streamlining the development process, these two new products will expand Transpire Bio’s reach as it looks to bring new, complex inhaled medicines to market.

“We are continuing our relentless pursuit of improving access to important, life-saving inhaled therapies, while methodically building capabilities for new inhaled therapies which will help address areas of significant unmet medical need,” said Xian-Ming Zeng, CEO of Transpire Bio. “With TRB-3 and TRB-4 we are demonstrating our ability to rapidly progress our pipeline in an effort to meet patient needs as quickly as possible. We are very excited to again be working with Recipharm to advance these important medicines.”

Jean-Francois Hilaire, executive committee member, head of business unit advanced delivery systems, Recipharm, said, “TRB-3 and TRB-4 are exciting developments for the treatment of two increasingly common chronic respiratory conditions. Recipharm is delighted to collaborate with Transpire Bio again and we will continue to share our extensive experience and expertise in developing and commercializing inhalation products to help bring these new inhaled medicines to market.”

According to statistics from the World Health Organization, asthma affected approximately 262 million people in 2019, and accounted for approximately 455,000 deaths. COPD was the third-leading cause of death in 2019, with approximately 3.2 million lives lost.

It was announced earlier this year that Transpire Bio had entered into an agreement with Recipharm for the development and commercialization of TRB-1 and TRB-2.